Robert Bosch Gesellschaft fuer medizinische Forschung mbH — Clinical Trial Site

46 Registered trials

23 Currently recruiting

Organisation

Robert Bosch Gesellschaft fuer medizinische Forschung mbH

Location

Stuttgart, Germany

Identifier

ORG-100014585

Address

Auerbachstraße 112, Bad Cannstatt, 70376, Germany

Departments

#3227:Kardiologie
127611: Robert-Bosch-Krankenhaus GmbH - Hämatologie, Onkologie und Palliativmedizin
Abteilung für Haematologie, Onkologie und Palliativmedizin
Abteilung für Hämatologie, Onkologie und Palliativmedizin
Abteilung für Pneumologie und Beatmungsmedizin
Abteilung für Pneumologische Onkologie
Abteilung Hämatologie, Onkologie und Palliativmedizin
Abteilungen Molekulare Onkologie und Pneumologische Onkologie
Allgemeine Innere Medizin und Nephrologie
Department of cardiovascular Surgery
Department of Hematology, Oncology and Palliative medicine
Gastroenterology, Hepatology and Endocrinology
General Internal Medicine and Nephrology
Gesellschaft für Medizinische Forschung mbH
gynaecologic oncology
Hämatologie, Onkologie und Palliativmedizin
Hämatologie,Onkologie u. Palliativmedizin,ZIM II
Herzzentrum
Innere Medizin
Institute of Clinical Pharmacology (IKP)
Interne I: Medizinische Onkologie und Hämatologie
Kardiologie und Angiologie
Lungenzentrum Stuttgart
N/A
na
Pneumologie und Pneumologische Onkologie
Pneumologische Onkologie
RBCT Gebäude
RBK Lungenzentrum Stuttgart am Robert-Bosch-Krankenhaus
Robert Bosch Gesellschaft für medizinische Forschung mbH
Robert Bosch Krankenhaus Lungenzentrum
Robert-Bosch-Krankenhaus (RBK)
Robert-Bosch-Krankenhaus, Hämatologie, Onkologie und Palliativmedizin

Clinical trials at this site (46)

Search interface

A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10… Recruiting

2023-507353-15-00 idiopathic pulmonary fibrosis (IPF) 5 2024-09-10
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended

2025-520521-21-00 Hyperlipidemia 5 2025-09-02
A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended

2024-518457-42-00 chronic kidney disease 4 2025-08-28
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended

2024-515740-23-00 Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-03-25
An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr… Ended

2024-517959-12-00 Relapsed/refractory B cell precursor acute lymphoblasti 9 2024-04-11
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or d… Ended

2024-513039-26-00 non-small cell lung cancer stages IIIA (N2) and selecte 4 2019-11-25
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended

2024-515783-31-00 Newly Diagnosed Multiple Myeloma 5 2018-08-24
Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF) Ended

2023-509371-16-00 Idiopathic Pulmonary Fibrosis 4 2024-09-25
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended

2023-510249-79-00 Progressive pulmonary fibrosis (PPF) 4 2024-09-10
A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering … Ended

2024-511076-32-00 Hypercholesterolemia 6 2024-06-21
A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended

2023-504678-39-00 Heart Failure 4 2024-03-13
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended

2024-512803-37-00 Progressive Fibrosing Interstitial Lung Diseases (PF-IL 5 2022-10-05
Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom… Ended

2024-511361-11-00 Advanced dedifferentiated liposarcoma 10 2022-03-25
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Lung Cancer, Non-Small Cell 5 2020-12-18
Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the ef… Ended

2023-507897-42-00 Prevention of oesophageal strictures in adult patients 4 2020-05-12
A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemothe… Ended

2023-504209-35-00 Early-Stage Resectable Non-small cell lung cancer (NSCL 5 2018-04-04
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem … Ended

2022-502040-13-00 High-risk Myelodysplastic neoplasia 4